SCHEMBL26964203

SCHEMBL26964203

N#Cc1cccc(S(=O)(=O)Nc2ccc(N3CCOCC3)c3cccnc23)c1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 8/20 0.74
▸ GLO1 Q04760 2/20 0.59
▸ PDE4D Q08499 1/20 0.45
▸ HTR6 P50406 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ AKT1 P31749 1/20 0.43
▸ PIK3CA P42336 1/20 0.43
▸ MTOR P42345 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ SCN9A Q15858 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CREBBP Q92793 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800803 1.00 SLC40A1 (0.74) SLC40A1GLO1PDE4DHTR6TDP1
SCHEMBL11973035 0.85 SLC40A1 (1.00) SLC40A1GLO1TDP1ALDH1A1LMNA
SCHEMBL30553444 0.83 SLC40A1 (0.72) SLC40A1TDP1ALDH1A1LMNASCN9A
SCHEMBL26964248 0.83 SLC40A1 (0.72) SLC40A1TDP1ALDH1A1LMNASCN9A
SCHEMBL17506516 0.81 SLC40A1 (0.82) SLC40A1TDP1ALDH1A1LMNAUSP2
SCHEMBL30925519 0.79 SLC40A1 (0.70) SLC40A1GLO1TDP1
SCHEMBL30553404 0.79 SLC40A1 (0.76) SLC40A1TDP1PIK3CAALDH1A1LMNA
SCHEMBL26964435 0.79 SLC40A1 (0.76) SLC40A1TDP1PIK3CAALDH1A1LMNA
SCHEMBL30925456 0.77 SLC40A1 (0.72) SLC40A1TDP1ALDH1A1LMNAUSP2
SCHEMBL30925584 0.77 SLC40A1 (0.72) SLC40A1GLO1TDP1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885GLO1 3779/4885PDE4D 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback